Tag: MSD

Lilly and Merck move on with oncology clinical trial of and Keytruda
November 19, 2015 Off

Lilly and Merck move on with oncology clinical trial of and Keytruda

By Dino Mustafić

Eli Lilly and Merck are moving on with an existing oncology clinical trial collaboration to evaluate the safety and efficacy of the combination of Lilly’s Almita (pemetrexed for injection) and Merck’s Keytruda (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

October 2, 2015 Off

Merck and DNAtrix to evaluate the efficacy and safety of DNX-2401

By Dino Mustafić

Merck, known as MSD outside the United States and Canada, and DNAtrix announced on Thursday that they have entered into an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrix’s oncolytic immunotherapy, in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase 2, multi-centered study of patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure.